Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 726-734

  Takeuchi, Kazuya ^a,b   Sugiura, Tomoko ^a   Matsubara, Kazuki ^a   Sato, Ren ^a   Shimizu, Takuya ^a   Masuo, Yusuke ^a   Horikawa, Masato ^b   Nakamichi, Noritaka ^a   Ishiwata, Norihisa ^b   Kato, Yukio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; ELTROMBOPAG; ROSUVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INHIBITION; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; INHIBITION KINETICS; INTESTINAL SECRETION; MALE; MAXIMUM PLASMA CONCENTRATION; MDCK CELL; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIMULATION; TRANSCYTOSIS;

ADULT; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOATES; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; COMPUTER SIMULATION; DOGS; DRUG INTERACTIONS; FLUOROBENZENES; HEK293 CELLS; HEPATOCYTES; HUMANS; HYDRAZINES; INTESTINE, SMALL; LLC-PK1 CELLS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; PYRAZOLES; PYRIMIDINES; RECEPTORS, THROMBOPOIETIN; SULFONAMIDES; SWINE;

EID: 84896113758     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054767     Document Type: Article

References (32)

1. Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, and Lee E (2011) Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol 72:321-329.
2. Bauman JW, Vincent CT, Peng B, Wire MB, Williams DD, and Park JW (2011) Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol 51:739-750.
3. Bourdet DL, Pritchard JB, and Thakker DR (2005) Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther 315:1288-1297. (Pubitemid 41635417)
4. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, and Stone NL, et al. (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357:2237-2247. (Pubitemid 350190754)
5. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, and Bussel JB (2011) Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 377:393-402.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
7. Deng Y, Madatian A, Wire MB, Bowen C, Park JW, Williams D, Peng B, Schubert E, Gorycki F, and Levy M, et al. (2011) Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos 39:1734-1746.
8. Erickson-Miller L, Delorme E, Giampa L, Hopson C, Valoret E, Tian SS, Miller SG, Keenan R, Rosen J, and Dillon S, et al. (2004) Biological activity and selectivity for TPO receptor of the orally bioavailable, small molecule TPO receptor agonist, SB-497115 (Abstract). Blood 104:2912.
9. Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, and Luengo JI, et al. (2009) Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells 27:424-430.
10. Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, and Kuroda M (1995) The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1254:7-12.
11. Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, and Kawara K, et al. (2014) Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. Pharm Res 31:204-215.
12. Huang L, Wang Y, and Grimm S (2006) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34:738-742.
13. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-412.
14. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, and Erickson-Miller CL (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109:4739-4741. (Pubitemid 46827766)
15. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
16. Kalliokoski A, Backman JT, Neuvonen PJ, and Niemi M (2008) Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics 18:937-942.
17. Kalliokoski A, Neuvonen PJ, and Niemi M (2010) SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 107:775-781.
18. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, and Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15:513-522. (Pubitemid 41017600)
19. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, and Niemi M (2009) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197-203.
20. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379-386.
21. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
22. Martin PD, Warwick MJ, Dane AL, Brindley C, and Short T (2003) Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25:2553-2563. (Pubitemid 37373930)
23. Sellers T, Hart T, Semanik M, and Murthy K (2004) Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs (Abstract). Blood 104:2063a.
24. Shimizu T, Sugiura T, Wakayama T, Kijima A, Nakamichi N, Iseki S, Silver DL, and Kato Y (2011) PDZK1 regulates breast cancer resistance protein in small intestine. Drug Metab Dispos 39:2148-2154.
25. Stasi R and Provan D (2004) Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 79:504-522. (Pubitemid 38401771)
26. Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, and Kubo Y, et al. (2010) PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine. Drug Metab Pharmacokinet 25:588-598.
27. Tachibana T, Kato M, Watanabe T, Mitsui T, and Sugiyama Y (2009) Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430-443.
28. Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, and Kato Y (2011) Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos 39:1088-1096.
29. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, and Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
30. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, and Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.
31. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, and Bergman A (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29:2860-2873.
32. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.